Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Following a lackluster 2024, shares of major drugmakers kicked off 2025 with an upbeat quarterly results reading. U.S. pharmaceuticals like Eli Lilly (LLY), Johnson & Johnson (JNJ), Bristol-Myers ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.

Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started, either. Here are two no-brainer healthcare stocks to buy with $500 right ...

New Delhi: Pfizer Ltd on Friday said its board has approved signing a marketing and supply agreement with Mylan ...

Pfizer has announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals for the marketing and sale of two of its brands, Ativan and Pacitane.

Mylan, which has an established presence in the central nervous system therapy segment, is expected to leverage its network ...